NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

I argued that all things point toward pending success or failure...

If so, then which is more important. That a phase 3 trial for a cancer therapy for GBM with essentially no side effects and early (open label small group) now mature clinical results that suggest strongly that there is very high efficacy for some large subgroup(s) may soon get approved or that it might soon get rejected?

Obviously the chance of approval is of far more significance than the chance of failure, whether you are talking from the investment perspective, the science perspective, the patient perspective, or the ethical perspective.